P3.12-10 Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1833
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.12-02 Dynamics of DLL3 and ASCL1 Expression in SCLC Over Disease Course

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-12 Genomic Profiling of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) Reveals Distinct Mutational Landscape

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MS32.04 Molecular Phenotypes of SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-01 Targeting Mitochondrial Metabolism as a Selective Therapeutic Approach in Small Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-17 a Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-03 Targeting DLL3 With AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) With Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.12-15 Distinctive Clinical Characteristics of SCLC in Never-Smokers

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Feedback Redefined: Principles and Practice

Journal of General Internal Medicine
Internal Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy